Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE2
180 participants
INTERVENTIONAL
2025-08-01
2028-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Lung ultrasound is a form of imaging that is fast, gentle and radiation free. However, it has not been routinely adopted into caring for preterm babies in most countries. This is because there are no randomised controlled trials that have demonstrated the benefit and safety of using lung ultrasound as the first-line imaging tool in preterm babies. The investigators will conduct a randomised controlled trial to demonstrate that lung ultrasound is a quick, safe and accurate alternative to chest x-rays in preterm babies.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Optimising Breathing Support at Extubation in Very Preterm Infants: A Clinical Study
NCT07251790
Neonatologist-Performed Lung Ultrasound (NPLUS) to Guide Respiratory Therapy
NCT06901206
Predictive Value of Lung Ultrasound for Respiratory Decompensation in Late Preterm Neonates
NCT07216053
Integrated Echocardiography and Chest Ultrasound Assessment of Lung Recruitment in Preterm Infants
NCT05726578
Lung Ultrasound as a Predictor of Mechanical Ventilation in Neonates Older Than 32 Weeks
NCT02449863
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Clearly, it is critical that clinicians have effective tools to guide breathing support. Currently, the only lung imaging tool that is routinely used in the Neonatal Intensive Care Unit is chest X-ray (CXR). The fundamental principle of use of ionising radiation in any population is to limit radiation exposure to as low as reasonably achievable (ALARA). To achieve this currently, the use of CXR is usually limited to once or twice a day. In addition CXR are performed by a specialised technician and are not always immediately available, delaying the time to diagnosis. Given the rapid and unpredictable changes in a preterm baby's lung disease, reliance on repeated CXR is fraught with risk. There is an urgent need to develop reliable tools that provides real-time and accurate feedback to guide breathing support in preterm babies.
New monitoring tools should be safe and improve outcomes. Lung ultrasound is a gentle form of lung imaging that is ideally suited for preterm babies. It is radiation free, readily available and does not require excessive handling of the baby. Ultrasound is already routinely used to image the brain and hearts of preterm babies and systems are available in all Neonatal Intensive Care Units in Australia. Several observational studies have demonstrated that lung ultrasound is accurate in diagnosing common neonatal respiratory disorders including pneumothorax, respiratory distress syndrome, transient tachypnoea of the newborn and the need for mechanical ventilation. Not all features of lung ultrasound are interchangeable with CXR measures of lung aeration in preterm infants. Lung ultrasound has a stronger relationship with an infant's respiratory support requirements than CXR. Only one study to date has assessed the ability of lung ultrasound to guide surfactant replacement in a randomized setting. Despite the growing body of evidence that lung ultrasound may be a suitable alternative to CXR, it has not been routinely adopted into clinical practice. This is because no randomized controlled trial has assessed the benefit and safety of using lung ultrasound as the first-line imaging tool in preterm babies. Furthermore, despite no evidence of benefit, some centres have already implemented lung ultrasound into routine practice. Before lung ultrasound can be widely implemented in preterm babies, it must be demonstrated to be beneficial and safe.
The investigators hypothesise that in preterm babies born \<32 weeks' gestation, lung ultrasound will significantly reduce radiation exposure and be a safe alternative to CXR. This will be addressed by conducting an open label, randomised controlled trial at Joan Kirner Women's and Children's, Sunshine Hospital, Victoria.
The primary aim of this study is to evaluate whether the use of lung ultrasound as the primary lung imaging modality in preterm babies born \<32 weeks' gestation reduces radiation burden.
Secondary aims include assessment of the safety and acceptability of lung ultrasound as the first line imaging tool, and additional signals of benefit including time to receive lung imaging and initiation of treatment, and duration of breathing support. To assess safety, the investigators will report the rate of key protocol defined adverse and serious adverse events in the intervention and control groups. Feasibility will be determined by protocol defined criteria for operational and clinical feasibility. Cost effectiveness will be determined by reporting the microcosts of each imaging tool and comparing the differential costs between the lung ultrasound and chest X-ray. Finally, the investigators will assess the acceptability to neonatal healthcare workers of lung ultrasound as the first-line imaging tool.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lung ultrasound group
Infants randomised to this group will have lung ultrasound as their first
Lung ultrasound group
Infants in the intervention arm will receive lung ultrasound as their first line imaging. Clinicians will be permitted to order a chest x-ray if they require further information or if the lung ultrasound findings are inconclusive or not consistent with the clinical findings.
Standard care
Infants in the standard arm will receive chest X-ray as their first form of lung imaging. Lung ultrasound will not be permitted in this group.
Standard Care
Infants in the standard group will receive chest X-ray as their first line imaging tool. Lung ultrasound will not be permitted in this group.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lung ultrasound group
Infants in the intervention arm will receive lung ultrasound as their first line imaging. Clinicians will be permitted to order a chest x-ray if they require further information or if the lung ultrasound findings are inconclusive or not consistent with the clinical findings.
Standard Care
Infants in the standard group will receive chest X-ray as their first line imaging tool. Lung ultrasound will not be permitted in this group.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The infant is born from 22 to 31+6 weeks' gestation by best obstetric estimate and admitted to the NICU
* The infant is considered to require lung imaging for respiratory indications
* The infant has a parent/guardian who can provide informed consent.
Exclusion Criteria
* The infant will only require CXR to be performed for specifically for non-respiratory indications i.e. assessment of cardiac silhouette
* The infant's Clinician has concern regarding clinical stability and tolerability of ultrasound scans
* The infant's skin integrity will not tolerate ultrasound gel
* Refusal of informed consent by their parent/guardian/legally acceptable representative
* The infant does not have a parent/guardian who can provide informed consent.
24 Hours
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Western Health, Australia
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Arun Sett
Neonatologist
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
115953
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.